海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

已收盘 02-13 15:00:00

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":7.48,"timestamp":1770966231000,"preClose":8.29,"halted":0,"volume":106575136,"delay":0,"changeRate":-0.0977,"floatShares":1616000000,"shares":1619000000,"eps":-0.207,"marketStatus":"已收盘","change":-0.81,"latestTime":"02-13 15:00:00","open":8.29,"high":8.37,"low":7.46,"amount":824000000,"amplitude":0.1098,"askPrice":7.48,"askSize":766,"bidPrice":7.47,"bidSize":1382,"shortable":0,"etf":0,"ttmEps":-0.207,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":8.29,"symbolType":"stock","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":9.12,"lowLimit":7.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":2.62,"roa":"--","roe":"0.14%","epsLYR":-0.21,"committee":0.665451,"marketValue":12108000000,"turnoverRate":0.066,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-24。","floatMarketCap":12085000000},"requestUrl":"/m/hq/s/002099","defaultTab":"news","newsList":[{"id":"2610925286","title":"大面积涨停！603000，1分钟封板！超23万手封死","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925286","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610925286?lang=zh_cn&edition=full","pubTime":"2026-02-10 12:15","pubTimestamp":1770696919,"startTime":"0","endTime":"0","summary":"2月10日上午，A股市场震荡调整，截至午间收盘，沪指跌0.02%，深成指跌0.02%，创业板指跌0.14%。消息面上，字节跳动近日发布Seedance2.0，可根据文本或图像创建电影级视频。消息面上，2025年中国创新药License-out总交易规模达到创纪录的1357亿美元。本次接续采购的药品覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、消化系统等26个治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210121931a491d273&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210121931a491d273&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1282651048.USD","LU0029875118.USD","LU0868486357.SGD","LU2242644610.SGD","LU0499858438.USD","LU0572944931.SGD","LU0228367735.SGD","LU0051755006.USD","JD","LU0791591158.USD","LU0348805143.USD","002099","LU0307460666.USD","LU0164880469.USD","LU0456827905.SGD","LU0672654166.SGD","LU0594300419.USD","LU2039709279.SGD","01211","LU0345775950.USD","LU1719994722.HKD","LU0543330483.HKD","IE00BGV7N243.SGD","LU0149721374.USD","BK1502","LU0828237510.HKD","LU0650527681.SGD","LU0417516738.SGD","LU1044875133.USD","LU0052750758.USD","06978","LU0588545730.USD","LU0871576103.HKD","LU0370786039.SGD","89618","LU1282651121.HKD","BK1574","BK1588","LU1303224171.USD","LU0359202008.SGD","LU1794554557.SGD","LU0259732245.USD","LU1282649067.USD","LU0384037296.USD","LU1642822792.SGD","LU0293314216.USD","LU1366334578.USD","BK1249","LU0314109678.HKD","BK1591","LU0865486749.SGD","SG9999002562.SGD","LU2257852520.SGD","LU0163747925.USD","LU0211977185.USD","SG9999002828.SGD","LU1044876610.USD","LU1224444064.USD","LU0588545904.SGD","BK1610","LU0588546209.SGD","LU0431992006.USD","BK1619","LU1770036033.HKD","BK1575","LU0488056044.USD","LU0315179316.USD","LU0345776255.USD","LU0359201885.HKD","BK1142","LU0228659784.USD","LU0128522157.USD","LU0048580855.USD","LU0417516902.SGD","LU0708995583.HKD","LU1282649810.SGD","LU1044874839.SGD","LU1813983027.USD","LU0531971595.HKD","LU0348735423.USD","LU0791590937.USD","300364","LU1366334651.USD","LU0469268626.HKD","LU1481107354.HKD","LU1251922891.USD","IE00B29SXG58.USD","LU1770034418.SGD","LU0456842615.SGD","LU0320764599.SGD","LU0359201612.USD","LU0084288322.USD","LU1808992512.USD","IE0032431581.USD","LU1023057109.AUD","LU1328277881.USD","LU0164865239.USD","SG9999001226.SGD","LU0348825331.USD","IE00B3M56506.USD","LU0140636845.USD","LU0315178854.USD","LU1720050803.USD","LU0231483743.USD","LU0320764755.SGD","300251","BK1161","BK1615","LU0039217434.USD","LU0327786744.USD","LU0456846285.SGD","LU0588545490.SGD","603000","LU0499858602.USD"],"gpt_icon":0},{"id":"2610696112","title":"异动快报：海翔药业（002099）2月10日10点11分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2610696112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610696112?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:15","pubTimestamp":1770689721,"startTime":"0","endTime":"0","summary":"证券之星2月10日盘中消息，10点11分海翔药业触及涨停板。其所属行业化学制药目前上涨。该股为染料，创新药，减肥药概念热股，当日染料概念上涨1.49%，创新药概念上涨0.59%，减肥药概念上涨0.46%。2月9日的资金流向数据方面，主力资金净流入738.48万元，占总成交额0.81%，游资资金净流出1224.28万元，占总成交额1.35%，散户资金净流入485.8万元，占总成交额0.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000010482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0077","BK0028","BK0188","BK0192","BK0239"],"gpt_icon":0},{"id":"2610501740","title":"异动快报：海翔药业（002099）2月9日9点32分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2610501740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610501740?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:35","pubTimestamp":1770600943,"startTime":"0","endTime":"0","summary":"证券之星2月9日盘中消息，9点32分海翔药业触及涨停板。其所属行业化学制药目前上涨。领涨股为诺诚健华。该股为染料，减肥药，新冠病毒防治概念热股，当日染料概念上涨4.14%，减肥药概念上涨0.91%，新冠病毒防治概念上涨0.8%。2月6日的资金流向数据方面，主力资金净流入1.01亿元，占总成交额13.73%，游资资金净流出4981.23万元，占总成交额6.77%，散户资金净流出5127.46万元，占总成交额6.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900002992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0077","BK0028","002099","BK0239","BK0188"],"gpt_icon":0},{"id":"2609537733","title":"异动快报：海翔药业（002099）2月6日11点4分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2609537733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609537733?lang=zh_cn&edition=full","pubTime":"2026-02-06 11:05","pubTimestamp":1770347119,"startTime":"0","endTime":"0","summary":"证券之星2月6日盘中消息，11点4分海翔药业触及涨停板。其所属行业化学制药目前上涨。领涨股为诺诚健华。该股为染料，化学原料药，医药概念热股，当日染料概念上涨3.56%，化学原料药概念上涨1.73%，医药概念上涨1.53%。2月5日的资金流向数据方面，主力资金净流出3379.43万元，占总成交额16.09%，游资资金净流出177.57万元，占总成交额0.85%，散户资金净流入3557.0万元，占总成交额16.94%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600014262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002099","BK0192","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2608180691","title":"股市必读：海翔药业(002099)股东户数3.05万户，较上期减少1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608180691","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608180691?lang=zh_cn&edition=full","pubTime":"2026-02-04 01:00","pubTimestamp":1770138038,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，海翔药业报收于6.92元，上涨1.62%，换手率4.62%，成交量74.71万手，成交额5.09亿元。来自公司公告汇总：截至2026年1月31日，公司已累计回购股份14,315,300股，占总股本的0.8844%，成交金额达8888.13万元。股本股东变化股东户数变动近日海翔药业披露，截至2026年1月30日公司股东户数为3.05万户，较1月20日减少451.0户，减幅为1.46%。户均持股数量由上期的5.23万股增加至5.31万股，户均持股市值为33.61万元。董秘： 您好，截止1月30日公司股东人数为30483人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400000672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0239","BK0192","BK0028","BK0077","BK0188"],"gpt_icon":0},{"id":"2608862209","title":"海翔药业（002099）披露股份回购进展情况公告，2月2日股价上涨7.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608862209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608862209?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:07","pubTimestamp":1770041239,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，海翔药业报收于6.81元，较前一交易日上涨7.58%，最新总市值为110.23亿元。该股当日开盘6.3元，最高6.96元，最低6.25元，成交额达6.88亿元，换手率为6.3%。近日，海翔药业发布《关于股份回购进展情况的公告》。公告显示，公司于2025年4月9日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金以集中竞价方式回购公司股份，用于股权激励或员工持股计划。回购进展符合相关规定及既定方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200038879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0192","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2606178020","title":"海翔药业（002099）披露获得地夸磷索钠化学原料药上市申请批准通知书，1月27日股价下跌2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606178020","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606178020?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:22","pubTimestamp":1769523744,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，海翔药业报收于6.27元，较前一交易日下跌2.03%，最新总市值为101.49亿元。该股当日开盘6.42元，最高6.42元，最低6.18元，成交额达1.36亿元，换手率为1.35%。近日，浙江海翔药业股份有限公司收到国家药品监督管理局核准签发的地夸磷索钠《化学原料药上市申请批准通知书》，批准该原料药注册。地夸磷索钠为P2Y2受体激动剂，用于干眼症治疗。2024年其滴眼液在中国城市公立医院销售额为13,089万元。未来生产销售时间及市场情况存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700041883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002099","BK0188","BK0192","BK0028"],"gpt_icon":0},{"id":"2605217292","title":"海翔药业：截止1月20日公司股东人数为30934人","url":"https://stock-news.laohu8.com/highlight/detail?id=2605217292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605217292?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:54","pubTimestamp":1768985650,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截至1月20日公司的股东人数为多少？海翔药业回复：您好，截止1月20日公司股东人数为30934人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0192","BK0239","002099","BK0188","BK0028"],"gpt_icon":0},{"id":"2604305131","title":"股市必读：海翔药业（002099）1月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604305131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604305131?lang=zh_cn&edition=full","pubTime":"2026-01-20 01:58","pubTimestamp":1768845490,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，海翔药业报收于6.54元，上涨0.31%，换手率1.22%，成交量19.67万手，成交额1.28亿元。公司公告汇总关于参投合伙企业投资复宏汉霖的进展公告浙江海翔药业股份有限公司出资1亿元参与设立杭州复宏股权投资合伙企业，专项投资于复宏汉霖的非上市股份。2026年1月19日，公司收到合伙企业通知，复宏汉霖已获中国证监会备案，其部分股东持有的境内未上市股份将转为H股并在香港联交所上市流通。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000000793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0192","BK0028","BK0188","BK0077","002099"],"gpt_icon":0},{"id":"2603660218","title":"海翔药业：截至1月9日股东人数为31210人","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660218?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:31","pubTimestamp":1768375874,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：截至1月9日公司股东人数为多少？海翔药业回复：您好，截止1月9日公司股东人数为31210人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002099","BK0077","BK0188","BK0192","BK0239"],"gpt_icon":0},{"id":"2603660229","title":"海翔药业：参投基金持有天兵科技1.352%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660229?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:27","pubTimestamp":1768375638,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！根据相关AI检索，贵公司通过某投资基金，参投了两家商业航天公司的相关股权。请介绍一下具体情况，穿透股权比例，及后续相关投资安排等。谢谢！海翔药业回复：您好，公司参投的寓鑫基金分别持有天兵科技和爱思达航天的1.352%股权和2.83%股权。根据公开信息，两家公司已启动了IPO辅导。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0077","002099","BK0192"],"gpt_icon":0},{"id":"2603657187","title":"海翔药业：公司未持有星河动力股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2603657187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603657187?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:35","pubTimestamp":1768275305,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：网传公司持有星河动力股票是否属实？如有请告知占股比例多少！谢谢海翔药业回复：您好，公司未持有星河动力股票。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300016068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002099","BK0188","BK0192","BK0077","BK0028"],"gpt_icon":0},{"id":"2602469615","title":"海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602469615","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602469615?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:32","pubTimestamp":1768228336,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，海翔药业报收于7.4元，较前一交易日上涨3.06%，最新总市值为119.78亿元。近日，浙江海翔药业股份有限公司与万邦德制药集团有限公司签订《创新药合作协议》。海翔药业作为资金提供方，将投入1.5亿元人民币，获得WP205产品全球商业化收益的15%。若2027年6月30日前未能启动III期临床或获得上市许可，海翔药业有权终止协议，万邦德制药需返还全部款项并支付年化3%资金使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0192","BK1574","BK0239","002099","159992","BK0077","BK0028","BK1161","BK0188"],"gpt_icon":0},{"id":"2602519380","title":"海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519380","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602519380?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215702,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司与万邦德制药签订《创新药合作协议》，双方将围绕渐冻症适应症开展相关合作，包括WP205产品的研发和商业化。海翔药业将提供1.5亿元资金，并享有产品商业化后15%的收益权益。该协议需经万邦德医药控股集团股份有限公司股东会审议通过后生效。存在法规政策、市场环境等风险，以及药品研发的高风险特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200029909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1161","BK1191","159992","002099","002082","BK0192","BK0239","BK1574","BK0028","BK0004","BK0188","06978","BK0077","BK0050"],"gpt_icon":0},{"id":"2601338955","title":"海翔药业：参投基金持有爱思达2.83%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601338955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601338955?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:55","pubTimestamp":1767833708,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问贵公司是否投资参股了爱思达航天公司？大概有多少股份？海翔药业回复：您好，公司参投的寓鑫基金持有天津爱思达航天科技股份有限公司2.83%股权。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800006225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0239","BK0028","BK0077","BK0188","BK0192"],"gpt_icon":0},{"id":"2601564978","title":"海翔药业：持有寓鑫基金约10.69%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601564978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601564978?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:33","pubTimestamp":1767659589,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，公司参投的基金持有天兵科技1.352%股份，目前公司持有该基金的份额大约多少或者占多少比例？海翔药业回复：您好，公司持有寓鑫基金约10.69%股权。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600006859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002099","BK0188","BK0077","BK0192"],"gpt_icon":0},{"id":"2601000914","title":"海翔药业（002099）披露股份回购进展情况，1月5日股价上涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000914?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:14","pubTimestamp":1767608098,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，海翔药业报收于6.43元，较前一交易日上涨3.04%，最新总市值为104.08亿元。该股当日开盘6.27元，最高6.72元，最低6.27元，成交额达2.98亿元，换手率为2.84%。公司近日发布公告，披露了关于股份回购的进展情况。浙江海翔药业股份有限公司于2025年4月9日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金通过集中竞价交易方式回购公司股份，用于股权激励或员工持股计划。回购进展符合相关规定和既定方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0188","BK0239","BK0028","BK0077"],"gpt_icon":0},{"id":"2595788890","title":"海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788890","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788890?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:11","pubTimestamp":1766995885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","06978","BK0077","BK0188","BK1161","BK0192","BK0028","002099","159992"],"gpt_icon":0},{"id":"2593349840","title":"海翔药业：截止12月19日公司股东人数为27172人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349840","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593349840?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:31","pubTimestamp":1766478670,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月20日股东人数是多少？海翔药业回复：您好，截止12月19日公司股东人数为27172人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0239","BK0028","BK0188","BK0077"],"gpt_icon":0},{"id":"2592787905","title":"海翔药业：研发经费分期支付不构成重大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2592787905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592787905?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:51","pubTimestamp":1766062270,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业12月17日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，根据《合作协议》规定，在合作期限内，研发经费将根据具体的合作项目按进度分期支付，不会对公司2025年度的财务状况、经营成果构成重大影响。国科大杭高院相关研究团队此前与产业界已有科研成果转化的成功案例，实际贡献经济效益。根据《深圳证券交易所股票上市规则》，公司目前不存在任何触及退市风险的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002099","BK0192","BK0028","BK0188","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771195205842,"stockEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0747},{"period":"3month","weight":0.1873},{"period":"6month","weight":0.2104},{"period":"1year","weight":0.499},{"period":"ytd","weight":0.1987}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30483人(较上一季度减少1.46%)","perCapita":"53003股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是医药及染料全产业链业务。公司的主要产品是原料药及医药中间体、合同定制业务、制剂、染料及染颜料中间体。公司已承担完成国家级项目13项，省级项目35项，拥有国内发明专利61项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}